Pfizer IIT-Delhi Innovation and IP Program

-
We posted about healthcare incubation initiative by Pfizer and IIT Delhi here, http://pharmaliterati.blogspot.in/2015/11/pfizer-iit-delhi-collaborate-for.html

An incubation accelerator co-created by Pfizer and FITT at IIT-Delhi.  The Pfizer IIT Delhi Innovation and IP Program (PIDIIP) will provide funding support of upto 50 lakhs to propel India's healthcare innovations from idea to IP.

The Pfizer-IIT Delhi Innovation and IP Program is a collaborative incubation accelerator - co-created by Pfizer and Foundation for Innovation and Technology Transfer (FITT) at the Indian Institute of Technology Delhi (IIT Delhi).

The Program will provide - funding, resources, expertise and infrastructure – to propel India’s healthcare innovations from idea to IP.

Pfizer funding through this program will provide an unencumbered grant of upto Rs. 50 lakhs to each innovator – selected through an appropriately drawn up process.

Patents obtained as a result of the incubation shall belong to the innovators, who will be free to commercialize them as they desire.

Two components of the Pfizer IIT Delhi Innovation & IP Program (PIDIIP)
  1. For innovators seeking comprehensive support to translate their healthcare ideas into new business opportunities, the Program provides:
    • Resident incubation at IIT Delhi’s bio-incubator for a period of up to 2 years.
    • Funding of upto INR 50 lakhs for each innovator to take ideas through proof of concept to IP.
    • Mentoring support from IIT Delhi’s faculty and FITT nominated experts.
    • Access to infrastructure, prototyping laboratories and space for setting up an office.
    • IP search and filing services.
    • Guidance from Pfizer’s global experts.
    • Access to venture capitalists and other industry linkages
  2. For innovators who already have a proof of principle /concept and are only looking for IP related support, the program provides:
    • Access to IP counselling services at FITT.
    • Funding support to cover patenting expenses.
 


 

Comments

Post a Comment

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

-
The China-India joint summit held recently discussed bilateral trade to improve Indo- China pharma industry and address issues like long product registration time and high fees for product registration in China’s drug regulatory system, among other issues.  Besides this, other relevant key issues related to transparency in public procurement system in China and clinical trial related approvals were also deliberated at the summit organised under the aegis of Indian Pharmaceutical Association (IPA), Shengjie and SaSPinjara, China between May 16 and May 17, 2019 at Pullman Shanghai South, China. The summit was focused on enhancing export business for both the nations across the globe. Senior health ministry official from Government of Gujarat Punamchand Parmar was invited as the Chief Guest of the summit and Gujarat Food and Drugs Control Administration (FDCA) Commissioner Dr Hemant Koshia was invited as Guest of Honour.  Among other dignitaries, Dr. Anil Kumar Rai, Consulate General of
Read more

Webinar on ‘OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH’

-
Image
“IDEA TO MARKET” is an idea hunt to commercialize the herbal inventions. It is a platform for researchers to use their innovative ideas in the area of herbal research and get the products commercialized in collaboration with corporate partners.  Hurry up and register for the webinar to know more about this program. The webinar is organized by Bombay College of Pharmacy and Pharma Literati.  Registration Link for webinar on OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH: https://docs.google.com/forms/d/e/1FAIpQLSfUhe1LtCOjG50SilFw_iECnzBXu4CW0nK2wIvd8QVVvpDOzQ/viewform
Read more